Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disoproxil fumarate

This page shows the latest tenofovir disoproxil fumarate news and features for those working in and with pharma, biotech and healthcare.

Gilead's Hepatitis B therapy Vemlidy granted EU approval

Gilead's Hepatitis B therapy Vemlidy granted EU approval

Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF

Latest news

  • ViiV takes two-drug cocktail for first-line HIV into phase III ViiV takes two-drug cocktail for first-line HIV into phase III

    three-drug regimen based on Tivicay and Gilead Sciences' double NRTI drug Truvada (tenofovir disoproxil fumarate/emtricitabine). ... HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    Gilead Sciences has added to its portfolio of HIV drugs in Europe after getting EMA approval for Odefsey, a three-drug combination based on its new tenofovir alafenamide (TAF) drug. ... It is a follow up to Gilead's $1.4bn Complera, which contains

  • Gilead bags EU approval for next-generation HIV drug Gilead bags EU approval for next-generation HIV drug

    Called Descovy, the drug is a new version of Gilead's $3.5bn-a-year Truvada (emtricitabine and tenofovir disoproxil fumarate or TDF) that replaces the TDF component with a new ... salt called tenofovir alafenamide (TAF).

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    Descovy (emtricitabine tenofovir alafenamide) can be paired with a range of third agents and is given at a dosage over 90% lower than Gilead's existing treatment Viread (tenofovir disoproxil fumarate). ... The FDA's approval was based on phase III trials

  • Gilead wins US approval for second TAF-based HIV drug Gilead wins US approval for second TAF-based HIV drug

    The new drug is a follow-up to Gilead's Complera - which contains emtricitabine, Janssen's rilpivirine and tenofovir disoproxil fumarate (TDF) - but replaces the latter with a new salt of ... tenofovir called tenofovir alafenamide (TAF).

More from news
Approximately 2 fully matching, plus 33 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics